MYLAN-EZETIMIBE ezetimibe 10 mg tablets bottle

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

ezetimibe, Quantity: 10 mg

Disponível em:

Alphapharm Pty Ltd

Forma farmacêutica:

Tablet

Composição:

Excipient Ingredients: microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; crospovidone; lactose monohydrate; croscarmellose sodium; hypromellose

Via de administração:

Oral

Unidades em pacote:

10, 5, 30

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Primary Hypercholesterolaemia,Ezetimibe administered alone, or with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),Ezetimibe, administered with a statin, is indicated for patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).

Resumo do produto:

Visual Identification: White to off white capsule shaped, bevelled edge tablet debossed with M on one side of the tablet and EE1 on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status de autorização:

Registered

Data de autorização:

2021-01-11